Diseño de una Estación de Trabajo para Personas con Discapacidad en Miembros Superiores Usando una Interfaz Cerebro Computador

This paper shows the design of work-station for work-related inclusion people upper-limb disability. The system involves the use of novel brain computer interface used to bridge the user-computer interaction. Our hope objective is elucidating functional, technological, ergonomic and procedural aspects to runaway operation station; with propose to scratch barrier to impossibility access to TIC’s tools and work done for individual disability person. We found access facility ergonomics, adaptability and portable issue of workstation are most important design criteria. Prototype implementations in workplace environment have TIR estimate of 43% for retrieve. Finally we list a typology of services that could be the most appropriate for the process of labor including: telemarketing, telesales, telephone surveys, order taking, social assistance in disasters, general information and inquiries, reservations at tourist sites, technical support, emergency, online support and after-sales services.  El presente trabajo presenta el diseño de una estación de trabajo para la inclusión laboral de personas en estado de discapacidad en miembros superiores. El sistema involucra el uso de una novedosa interfaz cerebro computador que sirve como puente entre el usuario y el ordenador. Nuestro objetivo es dilucidar los aspectos funcionales, tecnológicos, ergonómicos y procedimentales de la puesta en marcha de la estación de trabajo; con el fin de romper con las barreas que imposibilitan el acceso a las herramientas TIC’s y el trabajo por parte de las personas en estado de discapacidad en miembros superiores. Se encontró que la facilidad de acceso, la ergonomía, la adaptabilidad y la portabilidad de la estación de trabajo son los criterios de diseño más importantes. La implementación de este prototipo en una ambiente laboral tiene una TIR estimada de 43% para retribución. Finalmente se describe una tipología de servicios que podrían ser los más indicados para el proceso de inclusión laboral: telemarketing, televentas, encuestas telefónicas, toma de pedidos, ayuda social en catástrofes, información general y consultas, reservaciones en sitios turísticos, soporte técnico, emergencias, asistencia en línea y servicios posventa

Rehabilitation System based on the Use of Biomechanical Analysis and Videogames through the Kinect Sensor

El presente artículo muestra la creación de un novedoso sistema para la rehabilitación física de pacientes con múltiples patologías, a través de dinámicas con videojuegos de ejercicio (exergames) y el análisis de los movimientos de los pacientes usando un software desarrollado. Este sistema está basado en el uso del sensor Kinect para ambos fines: divertir al paciente en su terapia a través de exergames y proporcionarle al especialista una herramienta para el registro y análisis de datos de captura de movimiento (MoCap) tomados a través del sensor Kinect y procesados utilizando análisis biomecánico mediante la transformación angular de Euler. Todo el sistema interactivo se encuentra instalado en un centro de rehabilitación y actualmente se realizan investigaciones con diferentes patologías (stroke, IMOC, trauma craneoencefálico, entre otros), los pacientes realizan sus sesiones con el sistema interactivo mientras el especialista registra los datos para un posterior análisis, el cual se realiza en un software creado para dicho fin. El software arroja gráficas de movimiento en los planos sagital, frontal y rotacional de 20 puntos distribuidos en el cuerpo. El sistema final es portable, no-invasivo, económico, de interacción natural con el paciente y de fácil implementación por parte del personal médico.  This paper presents development of a novel system for physical rehabilitation of patients with multiple pathologies, through dynamic with exercise videogames (exergames) and analysis of the movements of patients using developed software. This system is based on the use of the Kinect sensor for both purposes: amusing the patient in therapy through of specialist exergames and provide a tool to record and analyze MoCap data taken through the Kinect sensor and processed using biomechanical analysis through Euler angles. All interactive system is installed in a rehabilitation center and works with different pathologies (stroke, IMOC, craneoencephallic trauma, etc.), patients interact with the platform while the specialist records data for later analysis, which is performed by software designed for this purpose. The motion graphics are shown in the sagittal, frontal and rotationalplanefrom20 points distributed in the body. The final system is portable, non-invasive, inexpensive, natural interaction with the patient and easily implemented for medical purposes

Baseline characteristics of patients in the reduction of events with darbepoetin alfa in heart failure trial (RED-HF)

<p>Aims: This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes.</p> <p>Methods and results: Key demographic, clinical, and laboratory findings, along with baseline treatment, are reported and compared with those of patients in other recent clinical trials in heart failure. Compared with other recent trials, RED-HF enrolled more elderly [mean age 70 (SD 11.4) years], female (41%), and black (9%) patients. RED-HF patients more often had diabetes (46%) and renal impairment (72% had an estimated glomerular filtration rate <60 mL/min/1.73 m2). Patients in RED-HF had heart failure of longer duration [5.3 (5.4) years], worse NYHA class (35% II, 63% III, and 2% IV), and more signs of congestion. Mean EF was 30% (6.8%). RED-HF patients were well treated at randomization, and pharmacological therapy at baseline was broadly similar to that of other recent trials, taking account of study-specific inclusion/exclusion criteria. Median (interquartile range) haemoglobin at baseline was 112 (106–117) g/L.</p> <p>Conclusion: The anaemic patients enrolled in RED-HF were older, moderately to markedly symptomatic, and had extensive co-morbidity.</p&gt

Enhanced production of Λb0\Lambda_{b}^{0} baryons in high-multiplicity pppp collisions at s=13\sqrt{s} = 13 TeV

The production rate of $\Lambda_{b}^{0}$ baryons relative to $B^{0}$ mesons in $pp$ collisions at a center-of-mass energy $\sqrt{s} = 13$ TeV is measured by the LHCb experiment. The ratio of $\Lambda_{b}^{0}$ to $B^{0}$ production cross-sections shows a significant dependence on both the transverse momentum and the measured charged-particle multiplicity. At low multiplicity, the ratio measured at LHCb is consistent with the value measured in $e^{+}e^{-}$ collisions, and increases by a factor of $\sim2$ with increasing multiplicity. At relatively low transverse momentum, the ratio of $\Lambda_{b}^{0}$ to $B^{0}$ cross-sections is higher than what is measured in $e^{+}e^{-}$ collisions, but converges with the $e^{+}e^{-}$ ratio as the momentum increases. These results imply that the evolution of heavy $b$ quarks into final-state hadrons is influenced by the density of the hadronic environment produced in the collision. Comparisons with a statistical hadronization model and implications for the mechanisms enforcing quark confinement are discussed.Comment: All figures and tables, along with machine-readable versions and any supplementary material and additional information, are available at https://cern.ch/lhcbproject/Publications/p/LHCb-PAPER-2023-027.html (LHCb public pages

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p&lt;0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (&lt;1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (&lt;1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality

Search for the Bs0 → μ+μ−γ decay

A search for the fully reconstructed B0 s → µ +µ −γ decay is performed at the LHCb experiment using proton-proton collisions at √ s = 13 TeV corresponding to an integrated luminosity of 5.4 fb−1 . No signifcant signal is found and upper limits on the branching fraction in intervals of the dimuon mass are set B(B 0 s → µ +µ −γ) &lt; 4.2 × 10−8 , m(µ +µ −) ∈ [2mµ, 1.70] GeV/c2 , B(B 0 s → µ +µ −γ) &lt; 7.7 × 10−8 , m(µ +µ −) ∈ [1.70, 2.88] GeV/c2 , B(B 0 s → µ +µ −γ) &lt; 4.2 × 10−8 , m(µ +µ −) ∈ [3.92, mB0 s ] GeV/c2 , at 95% confdence level. Additionally, upper limits are set on the branching fraction in the [2mµ, 1.70] GeV/c2 dimuon mass region excluding the contribution from the intermediate ϕ(1020) meson, and in the region combining all dimuon-mass intervals

First observation of the Λb0 → D+D−Λ decay

The Λ 0 b → D+D−Λ decay is observed for the first time using proton-proton collision data collected by the LHCb experiment at a center-of-mass energy of 13 TeV, corresponding to an integrated luminosity of 5.3 fb−1 . Using the B0 → D+D−K0 S decay as a reference channel, the product of the relative production cross-section and decay branching fractions is measured to be R = σΛ0 b σB0 × B(Λ0 b → D+D−Λ) B(B0 → D+D−K0 S ) = 0.179 ± 0.022 ± 0.014 , where the first uncertainty is statistical and the second is systematic. The known branching fraction of the reference channel, B(B0 → D+D−K0 S ), and the cross-section ratio, σΛ0 b /σB0 , previously measured by LHCb are used to derive the branching fraction of the Λ 0 b → D+D−Λ decay B(Λ0 b → D+D−Λ) = (1.24 ± 0.15 ± 0.10 ± 0.28 ± 0.11) × 10−4 , where the third and fourth contributions are due to uncertainties of B(B0 → D+D−K0 S ) and σΛ0 b /σB0 , respectively. Inspection of the D+Λ and D+D− invariant-mass distributions suggests a rich presence of intermediate resonances in the decay. The Λ 0 b → D∗+D−Λ decay is also observed for the first time as a partially reconstructed component in the D+D−Λ invariant mass spectrum

Measurements of the branching fraction ratio B(ϕ → μ+μ−) / B(ϕ → e+e−) with charm meson decays

Measurements of the branching fraction ratio B(ϕ → μ+μ−) / B(ϕ → e+e−) with Ds+→π+ϕ and D+→ π+ϕ decays, denoted Rϕπs and Rϕπd, are presented. The analysis is performed using a dataset corresponding to an integrated luminosity of 5.4 fb−1 of pp collision data collected with the LHCb experiment. The branching fractions are normalised with respect to the B+ → K+J/ψ(→ e+e−) and B+ → K+J/ψ(→ μ+μ−) decay modes. The combination of the results yieldsRϕπ=1.022±0.012stat±0.048syst. The result is compatible with previous measurements of the ϕ → ℓ+ℓ− branching fractions and predictions based on the Standard Model